RVNC
Revance Therapeutics Inc
Price:  
2.67 
USD
Volume:  
2,999,076.00
United States | Pharmaceuticals
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

RVNC EV/EBITDA

-1464.9%
Upside

As of 2024-05-24, the EV/EBITDA ratio of Revance Therapeutics Inc (RVNC) is -2.82. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RVNC's latest enterprise value is 575.50 mil USD. RVNC's TTM EBITDA according to its financial statements is -203.83 mil USD. Dividing these 2 quantities gives us the above RVNC EV/EBITDA ratio.

Note: valuation result may not be accurate due to the company's negative EBITDA.

Range Selected
Trailing P/E multiples 10.1x - 17.9x 14.1x
Forward P/E multiples 18.5x - 20.6x 20.2x
Fair Price (39.07) - (37.90) (36.44)
Upside -1563.4% - -1519.4% -1464.9%
2.67 USD
Stock Price
(36.44) USD
Fair Price

RVNC EV/EBITDA - Historical EV/EBITDA Data

Date EV/EBITDA
2024-05-24 -2.84
2024-05-23 -2.82
2024-05-22 -2.95
2024-05-21 -3.00
2024-05-20 -3.07
2024-05-17 -3.00
2024-05-16 -3.07
2024-05-15 -3.15
2024-05-14 -3.24
2024-05-13 -3.16
2024-05-10 -3.16
2024-05-09 -3.65
2024-05-08 -3.64
2024-05-07 -3.70
2024-05-06 -3.55
2024-05-03 -3.48
2024-05-02 -3.39
2024-05-01 -3.40
2024-04-30 -3.30
2024-04-29 -3.34
2024-04-26 -3.20
2024-04-25 -3.14
2024-04-24 -3.28
2024-04-23 -3.33
2024-04-22 -3.32
2024-04-19 -3.39
2024-04-18 -3.40
2024-04-17 -3.38
2024-04-16 -3.41
2024-04-15 -3.49
2024-04-12 -3.57
2024-04-11 -3.73
2024-04-10 -3.71
2024-04-09 -3.86
2024-04-08 -3.73
2024-04-05 -3.71
2024-04-04 -3.71
2024-04-03 -3.78
2024-04-02 -3.76
2024-04-01 -3.88
2024-03-28 -3.97
2024-03-27 -3.98
2024-03-26 -3.86
2024-03-25 -3.84
2024-03-22 -3.95
2024-03-21 -4.11
2024-03-20 -4.05
2024-03-19 -3.98
2024-03-18 -3.98
2024-03-15 -4.17